From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Videos|January 27, 2022
Expert Discusses How Blockchains Could Impact The Future of Pharmacy
Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.
Advertisement
Brian Thornley, the Associate Vice President of Supply Excellence, Innovation and Digital Strategy at Merck, discusses what makes blockchain unique and what it could mean down the road for pharmacies.
He addressed the limitations of blockchain, the regulation and legislation that should be considered, and other potential uses for blockchain in health care.
Advertisement
Related to this article
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Earlier PRRT in Neuroendocrine Tumors Puts Pharmacists at the Center of Coordination
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5